MetaVia (NASDAQ:MTVA) Earns Buy Rating from Analysts at HC Wainwright

Analysts at HC Wainwright assumed coverage on shares of MetaVia (NASDAQ:MTVAGet Free Report) in a research report issued to clients and investors on Monday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $12.00 price target on the stock.

MetaVia Trading Down 2.8 %

MTVA opened at $1.76 on Monday. MetaVia has a 12 month low of $1.51 and a 12 month high of $6.75.

About MetaVia

(Get Free Report)

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.

Featured Articles

Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.